0 results for 'Anda Pharmaceuticals, Inc.'
Suit Claiming COPD Inhaler's Design, Maker's Defect Is Dismissed as Federally Preempted
New York Attorney General Announces Settlement With Three Opioid Distributors Amid Long Island Trial
The settlement with McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Drug Corp. will bring up to $1.1 billion for opioid treatment, recovery and prevention efforts in New York.Plaintiff moved to stay the parties' claims and counterclaims pending resolution of its appeal of a similar case in Delaware.
Delaware Patent Filings Dipped in 2020 Thanks to Fewer New Drug Filings
COVID-related restrictions, a drop in Abbreviated New Drug Application filings and plaintiffs' strategizing on where and how frequently to file all played a role in Delaware seeing 26% fewer patent filings in 2020 and losing its place as the top venue for patent litigation to the Western District of Texas.Fewer New Drug Filings Helped Drive 2020 Dip in Delaware Patent Filings, Report Finds
COVID-related restrictions, a drop in Abbreviated New Drug Application filings and plaintiffs' strategizing on where and how frequently to file all played a role in Delaware seeing 26% fewer patent filings in 2020 and losing its place as the top venue for patent litigation to the Western District of Texas.Federal Circuit Tries To Demystify Venue in Hatch-Waxman Actions
The Federal Circuit found that "acts of infringement" for venue purposes occur "only in districts where actions related to the submission of an Abbreviated New Drug Application (ANDA) occur, not in all locations where the future distribution of the generic products specified in the ANDA is contemplated."Wilson Sonsini Helps Mylan Tighten Venue Rules for Pharma Litigation
Thursday's ruling means fewer pharmaceuticals may bring Hatch-Waxman Act lawsuits in the popular venues of Delaware and New Jersey.With the Help of Wilson Sonsini, Mylan Tightens Venue Rules for Pharma Litigation
Thursday's ruling means fewer pharmaceuticals may bring Hatch-Waxman Act lawsuits in the popular venues of Delaware and New Jersey.With the Help of Wilson Sonsini, Venue Rules Tighten for Pharma Patent Litigation
Thursday's ruling means fewer pharmaceuticals may bring Hatch-Waxman Act lawsuits in the popular venues of Delaware and New Jersey.COVID-19 and Hatch-Waxman Litigation in the District of New Jersey
Despite the overall reduction in Hatch-Waxman cases and filings, cases have continued to move forward—albeit with COVID-19-related modifications.Corporate Transparency Act Resource Kit
Brought to you by Wolters Kluwer
Download Now
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now